Challenging the Rheumatoid Arthritis treatment standards with JAK inhibitors
This Lilly satellite symposium, “Challenging the Rheumatoid Arthritis treatment standards with JAK inhibitors” will explore the integrated approach to improving our understanding of the impact of specific domains of chronic systemic disease, like Rheumatoid Arthritis, on the every-day-life of our patients.
The expert panel of presenters will review the recent improvements in patient management, as well as those areas that remain open to improvement, in the context of the current and emerging molecular mechanism of JAK inhibition.
The symposium will be chaired by Prof. Wen-Chan Tsai, from Taiwan, and will address three key areas:
- Review the innovative MoA of the JAK inhibitors
Prof. Yoshiya Tanaka, from Japan, will share with the audience the latest discoveries on the effects of the JAK pathways inhibition, how this has affected the inflammation cascade and how we can use this as a new approach to efficiently treat patients with Rheumatoid Arthritis.
- Address the unmet need in the treatment of Rheumatoid Arthritis patients
Dr. Reike Alten, from Germany, will explore the role of the Patient-reported Outcomes and how they can influence choice among the different treatments options in light of shared decision-making. She will include in her presentation the most recent data on safety and efficacy of the JAKs inhibitor class.
- Explain how JAK inhibitors differ from Standard of Care and discuss their ideal position in the Rheumatoid Arthritis treatment algorithms
Dr. Andrew Östör, from Australia, will analyse the position of this new class in the different major guidelines and recommendations, and define the profile of the patient who can best benefit from this.
We hope that you find this symposium a valuable forum for discussing the impact and areas of improvement in the treatment of chronic inflammation in Rheumatoid Arthritis.
Prof. Wen-Chan Tsai, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Prof. Yoshiya Tanaka, University of Occupational and Environmental Health, Kitakyushu, Japan
Prof. Rieke Alten, University Medicine Berlin, Berlin, Germany
Dr. Andrew Östör, Cabrini Medical Centre, Melbourne, Australia
1300 – Welcome and introduction – Chair
1305 – JAK inhibitors – Are they all the same? – Prof. Yoshiya Tanaka
1325 – Perception of the burden for a Rheumatoid Arthritis patient: Is it really just about inflammation? – Prof. Rieke Alten
1345 – Positioning of JAK inhibitors in the treatment algorithm of Rheumatoid Arthritis – Dr. Andrew Östör
1405 – Panel discussion and Q&A
1430 – Symposium close